ARIAD Completes Rolling Submission of NDA for Brigatinib to the U.S. FDA

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2016-- ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK)...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news